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Background: A new version of international standard (ISO 15197) and CLSI Guideline (POCT12) with more
stringent accuracy criteria are near publication. We evaluated the glucose test performance of the FreeStyle
Precision Pro system, a new blood glucose monitoring system (BGMS) designed to enhance accuracy for
point-of-care testing (POCT).
Methods: Precision, interference and system accuracy with 503 blood samples from capillary, venous and
arterial sources were evaluated in a multicenter study. Study results were analyzed and presented in accor-
dance with the speciﬁcations and recommendations of the ﬁnal draft ISO 15197 and the new POCT12.
Results: The FreeStyle Precision Pro system demonstrated acceptable precision (CV b5%), no interference
across a hematocrit range of 15–65%, and, except for xylose, no interference from 24 of 25 potentially inter-
fering substances. It also met all accuracy criteria speciﬁed in the ﬁnal draft ISO 15197 and POCT12, with
97.3–98.9% of the individual results of various blood sample types agreeing within ±12 mg/dl of the labora-
tory analyzer values at glucose concentrations b100 mg/dl and within ±12.5% of the laboratory analyzer
values at glucose concentrations ≥100 mg/dl.
Conclusions: The FreeStyle Precision Pro systemmet the tighter accuracy requirements, providing a means for
enhancing accuracy for point-of-care blood glucose monitoring.© 2013 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Since it is often unfeasible or difﬁcult to obtain laboratory blood
glucose measurements as frequently or as rapidly as required for pa-
tients in acute or chronic care facilities, point-of-care (POC) blood glu-
cose testing is a valuable tool for the management of patients with
diabetes and other conditions, providing rapid blood glucose results
for therapeutic decision-making. Recently more attention has been
drawn to the accuracy requirements for blood glucosemonitoring sys-
tems (BGMS) for home use as well as those for hospital use. Interna-
tional standard (ISO 15197:2003) [1], CLSI guideline (NCCLS C30-A2)
[2] and FDA [3] specify the minimum acceptable system accuracy
for BGMS, requiring≥95% of the individual glucose results to fall with-
in ±15 mg/dl of the results of the reference measurements at glucose
concentration b75 mg/dl and within ±20% at glucose concentrations
≥75 mg/dl.
Versions of ISO 15197 [4] and CLSI Guideline (POCT12) [5] with
more stringent accuracy criteria are near publication. It has been60 South Loop Rd., Alameda,
 -ND license.proposed that the new ISO standard would require each BGMS to
meet 2 accuracy criteria: Criterion A — 95% of the measured glucose
values shall fall within ±15 mg/dl of the average measured values
of the reference measurement procedure at glucose concentrations
b100 mg/dl or within ±15% at glucose concentrations ≥100 mg/dl;
Criterion B — 99% of individual glucose measured values shall fall
within zones A and B of the Consensus Error Grid for type 1 diabetes
[6]. The number of acceptable results at glucose concentrations
b100 mg/dl shall be added to the number of acceptable results at
glucose concentrations ≥100 mg/dl before applying the accuracy
criteria. Criterion A shall be applied to each test strip lot individually;
Criterion B shall be applied to the results pooled from 3 test strip lots.
The new POCT12 recommends that meter performance, based on
at least 100 patients and 200 results, meets both of the following
criteria: (1) ≥95% of the individual results from the POC BGMS
agree within ±12 mg/dl of the laboratory analyzer values at glucose
concentrations b100 mg/dl and within ±12.5% of the laboratory
analyzer values at glucose concentrations ≥100 mg/dl; (2) ≥98% of
the individual results from the POC BGMSmeet the previous accuracy
criterion (i.e., agreeing within ±15 mg/dl of the laboratory analyzer
values at glucose concentrations b75 mg/dl and within ±20% of the
laboratory analyzer values at glucose concentrations ≥75 mg/dl).
Table 1
Precision.
Meana glucose, mg/dl Repeatability Intermediate Precision
SDa, mg/dl CVa, % Pooled SD, mg/dl Pooled CV, % SDa, mg/dl CVa, % Pooled SD, mg/dl Pooled CV, %
45–46 2.0–2.4 4.4–5.4 2.2 – 2.4–2.6 5.3–5.8 2.5 –
89–93 3.0–3.4 3.2–3.9 3.3 – 3.6–4.2 3.9–4.7 3.8 –
137–140 4.0–4.6 2.9–3.4 – 3.2 5.0–6.4 3.6–4.7 – 4.1
216–223 6.2–7.1 2.8–3.2 – 2.9 7.7–8.7 3.5–4.0 – 3.7
356–375 8.5–12.0 2.4–3.2 – 2.9 12.2–16.8 3.4–4.7 – 3.9
a Ranges of values for 3 test strip lots with 100 tests per lot.
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taken together before applying the accuracy criteria.
We evaluated the glucose test performance of the FreeStyle Preci-
sion Pro system, a new BGMS designed to enhance accuracy for point-
of-care testing (POCT). The study results were analyzed and pres-
ented using the newly proposed accuracy requirements from the
draft standard and guideline.
2. Materials and methods
2.1. The FreeStyle Precision Pro system
The Freestyle Precision Pro Blood Glucose and β-Ketone Monitor-
ing System is designed to simplify POCT for healthcare professionals,
providing features that enhance the reliability of the testing process
and support compliance with POCT policies.
The FreeStyle Precision Pro meter is ergonomically designed for
one-hand operation. It has a built-in camera to scan one dimensional
and two dimensional barcodes. The meter can automatically upload
data wirelessly in a WiFi enabled facility when the meter and data
management systems are properly conﬁgured.
The FreeStyle Precision Pro blood glucose test strip is individually
sealed in a foil packet to protect it from unintended exposure to mois-
ture or chemicals and cross-contamination by bacteria or viruses. Each
test strip contains three electrodes (working, reference, and ﬁll trigger).
The circuit between the ﬁll trigger and the reference electrodesmust be
detected by themeter before the test will start. The completed circuit is
only detectedwhen the applied sample ﬂows beyond the reference and
working electrodes to contact the ﬁll trigger electrode. This designmin-
imizes errors due to insufﬁcient sample and reduces strip waste. Upon
application of sufﬁcient sample, the test is automatically initiated. Glu-
cose dehydrogenase (GDH-NAD), coenzyme (NAD+), and an electron
mediator (PQ) are present on the working electrode of the test strip.
The GDH catalyses the oxidation of glucose by NAD+ to gluconolactone
and the coenzymeNAD+ is reduced to NADH. The electronmediator re-
acts with the reduced coenzyme (NADH), thus the mediator is reduced
and the co-enzyme returns to its oxidized state (NAD+). The reduced
mediator is oxidized at the working electrode, which produces a small
electric current proportional to the glucose concentration in the sample.
The current ismeasured by themeter. Theminimumsample volume re-
quired is 0.6 μL and the test time is 5 s.Table 2
Interference testing — hematocrit.
Glucose concentration, mg/dl Mean biasa from control (hematocr
15% 20%
40–50 0.9/2.9 −2.1/2.2
100–120 −1.5/2.6 −3.0/2.2
210–230 1.3/3.4 −1.6/3.3
330–350 −1.1/2.8 −1.0/3.5
440–460 −4.5/5.1 −4.5/4.6
Mean bias (mg/dl) at glucose b100 mg/dL 1.9 0.0
Mean bias (%) at glucose ≥100 mg/dl 1.5 0.3
a Range of values for 3 strip lots.2.2. Precision evaluation
Precision evaluation was conducted in accordance with the ﬁnal
draft ISO 15197 [4]. Repeatability was evaluated using 10 meters, 3
test strip lots, and 5 venous blood samples with glucose concentra-
tions adjusted to represent hyperglycemic, euglycemic and hypogly-
cemic conditions and matching the ﬁve concentration ranges
speciﬁed in the ﬁnal draft ISO 15197; 10 measurements were made
with each combination of meter, test strip lot and sample. Intermedi-
ate precision was evaluated using 10 meters, three test strip lots and
three levels of control solutions representing hyperglycemic,
euglycemic and hypoglycemic conditions; each sample was tested
in duplicate with 10 meters on each of 20 days.
2.3. Interference testing — hematocrit
Evaluation of hematocrit effects was conducted with seven he-
matocrit levels, ﬁve glucose concentrations and three test strip lots.
The venous blood sample was adjusted to the 5 glucose concentra-
tions and 7 hematocrit levels (±1% of 15%, 20%, 30%, 42% (control
sample), 50%, 60% and 65%) by separating the plasma from the cells,
then adding aliquots of plasma to packed cells in different propor-
tions as described in the ﬁnal draft ISO 15197 [4]. Each of the 35 ad-
justed samples was tested on 10 meters with each strip lot. Each
sample was also tested on the YSI 2300 Stat Plus glucose analyzer
and the results were used to calculate biases of the meter results. To
determine hematocrit effects, the difference between the average
glucose bias and the average bias of the hematocrit control sample
was calculated for each sample. An interference effect is deﬁned as
meeting one of the following criteria: (1) for glucose concentrations
b100 mg/dl, the difference between test sample mean value and con-
trol sample mean value >10 mg/dl; (2) for glucose concentrations
≥100 mg/dl, the difference between test sample mean value and
control sample mean value >10%.
2.4. Interference testing — interfering substances
Interference testing and data analysis were conducted in accor-
dance with the ﬁnal draft ISO 15197. Twenty-ﬁve substances were
tested for interference with venous blood in two glucose concentra-
tion ranges (50–100 mg/dl and 250–350 mg/dl) and three test stripit, 42%)
30% 50% 60% 65%
0.4/2.7 −1.0/5.1 −5.0/−1.1 −2.4/2.7
2.1/7.0 −4.7/4.0 −4.0/3.5 −1.3/8.0
−1.1/7.7 −6.0/−0.8 −3.7/−0.8 −4.5/−0.3
−1.5/6.2 −0.1/0.1 −6.4/−2.1 −4.1/−1.5
−1.2/3.4 −4.7/5.1 −5.4/−1.9 −8.5/2.6
1.6 1.2 −3.7 −0.1
2.7 −1.2 −2.9 −0.9
Fig. 1. Bias for arterial blood glucose results versus sample hematocrit values Regres-
sion analysis showed: slope = −0.01, intercept = 0.9, r = −0.008, n = 360.
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sured glucose values from samples with an added substance to a con-
trol sample without the added substance. Ten measurements were
made with each combination of meter, test strip lot and sample. The
YSI 2300 Stat Plus glucose analyzer was used to assign glucose refer-
ence values to the samples. The average of the measured values from
the blood-glucose monitoring system was calculated for each sample,
followed by calculating the difference between the average of the test
sample values and the average of the control sample values. An inter-
ference effect is deﬁned above in Section 2.3.
2.5. Accuracy evaluation — capillary blood testing
A system accuracy evaluation on capillary blood testing was
conducted using 3 lots of test strips at 2 clinical research centers en-
rolling 150 subjects. Twenty samples were modiﬁed to provideTable 3
Interference testing — interfering substances.
Substance, mg/dl Upper limit of therapeutic or normal
concentration [10,11], mg/dl
Test conce
mg/dl
Acetaminophen 3 20
Ascorbate 1.5 2.5
Beta-hydroxybutyrate b7.6 100
Bilirubin (unconjugated) 1.2 20
Cholesterol b200 500
Creatinine 1.3 30
Dopamine 0.03 13
EDTA 180 720
Ephedrine 0.01 10
Galactose 20 100
Heparin 15a 60a
Ibuprofen 5 50
L-Dopa 0.2 5
Lactate 20 100
Lactose – 100
Maltose 120 200
Methyl-Dopa 0.75 2.5
Pyruvate 0.9 10
Salicylic acid 30 50
Tetracycline 0.5 4
Tolazamide 2.8 100
Tolbutamide 10 100
Triglycerides b150 3000
Uric acid 7.2 40
Xylose 50 100
a Heparin concentration in IU/ml.additional samples with low and high glucose concentrations:
≤50 mg/dl (5 samples), 51–80 mg/dl (7 samples), 301–400 mg/dl
(2 samples), >400 mg/dl (6 samples). In accordance with the ﬁnal
draft ISO 15197 [4], blood samples collected with an appropriate anti-
coagulant were supplemented with a 0.9% saline solution containing a
high concentration of glucose to prepare high glucose samples; the sup-
plemented sampleswere allowed to stand for at least 15 min before use
to allow the added glucose to equilibrate between the plasma and red
blood cells. To prepare low glucose samples, blood samples collected
with an appropriate anticoagulantwere incubated at 37 °C to allow gly-
colysis to occur [4]. Each blood sample in the study was tested in dupli-
cate with three lots of test strips (n = 6 tests). To assess accuracy, a YSI
2300 Stat Plus glucose analyzer served as comparative method to test
each sample in duplicate. The YSI glucose analyzer, with metrological
traceability to CDC hexokinasemethod and NIST certiﬁed referencema-
terials, is the referencemeasurement procedure used bymostmanufac-
turers of blood glucose monitoring systems. To minimize potential
effect of glycolysis, all meter and YSI blood tests were completedwithin
20 min. To verify sample and YSI stability, the 2 YSI results must agree
within ±4 mg/dl at glucose ≤100 mg/dl or 4%, at glucose concentra-
tions >100 mg/dl, for the test results to be accepted. The YSI whole
blood glucose result was multiplied by 1.12 to obtain a plasma equiva-
lent glucose value for comparisonwith the BGMS results. For daily qual-
ity control, three levels of glucose standards were tested on the YSI
analyzer, and the Mid Level of control solution was tested on the Free-
Style Precision Pro Systems. Before testing each blood sample on the
YSI analyzer, the calibrator (180 mg/dl; traceable to NIST SRM 917a)
was tested and the result must be within 176–184 mg/dl before pro-
ceeding with the blood sample. Passing and Bablok regression [7] was
used to calculate the slope and intercept, comparing the BGMS response
(Y or dependent variable) to the reference method (X or independent
variable). BGMS results were compared with the YSI results using the
newly proposed accuracy criteria from the draft standard and guideline.
2.6. Accuracy evaluation — venous blood testing
The study was conducted at a clinical research center enrolling
110 subjects. Each subject provided two tubes of venous blood (one
anticoagulated with heparin and the other with EDTA). Each venousntration, Bias (mg/dl) from control
at glucose of 50–100 mg/dl
Bias (%) from control at glucose
of 250−350 mg/dl
1.0 −1.7
9.6 4.1
−1.4 0.6
1.6 2.3
0.7 −0.2
0.6 0.8
7.7 3.3
−0.2 −3.6
0.3 −1.4
−0.2 −1.8
−3.9 −3.3
−1.3 3.2
1.7 1.1
2.0 −0.3
3.4 1.7
−0.8 0.2
0.5 −0.9
0.0 −1.7
−1.2 −1.7
0.4 0.6
2.8 1.1
−0.7 0.6
−2.6 −4.4
−1.2 −3.1
17.0 5.5
Fig. 2. Scatter plot (A) and bias plot (B) for capillary blood glucose results. (A) Regres-
sion analysis showed: slope = 1.01, intercept = −2.5 mg/dL, r = 0.99, n = 973. (B)
Analysis showed: mean bias = −1.9 mg/dL or−1.5%, mean absolute bias (MARD) =
5.0%, n = 973.
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using 6 meters and in duplicate with a YSI 2300 Stat Plus glucose an-
alyzer. Quality control and data management were identical to those
in the capillary blood study.
2.7. Accuracy evaluation — arterial blood testing
The study was conducted with 120 leftover arterial blood samples
from the blood gas laboratory that serves mainly intensive care unit
and operating room patients at a medical center. The arterial blood
samples were tested with three FreeStyle Precision Pro Systems
using 3 lots of test strips and in duplicate with the YSI 2300 Stat
Plus glucose analyzer. The hemoglobin result was obtained from the
blood gas analysis and converted to a hematocrit estimate. Quality
control and data management were the same as those in the capillary
blood study. The study protocol used at each study site was reviewed
and approved by an institutional review board. Informed consent was
obtained from each participant except when it was not required for
the use of leftover arterial blood samples with no identiﬁable subject
information [8].
2.8. Statistical analysis
All statistical analyses for the clinical studies were performed
using SAS® ver 9.2 or higher (SAS Institute Inc., Cary, NC). Passing–
Bablok regression analysis [7] was used to correlate meter results
with comparative method values in clinical evaluations. Passing–
Bablok regression analysis is recommended by the American Associa-
tion of Bioanalysts [9] for method comparison (accuracy) studies.
Mean absolute relative difference (MARD) between meter results
and YSI analyzer results was calculated with all results of each sample
type to access the mean absolute bias. Data were excluded from
statistical analysis if (1) the drift between the ﬁrst and second mea-
surements of the comparative method was >4 mg/dl at glucose
≤100 mg/dl or >4% at glucose >100 mg/dl, (2) test time exceeded
the speciﬁed interval, or (3) the data set was not complete. The inci-
dence of data exclusion in the accuracy studies was under 1.0%. Labo-
ratory study results were evaluated using JMP ver 5.1 statistical
software (SAS Institute).
3. Results
3.1. Precision
As shown in Table 1, the pooled SD was b5 mg/dl at glucose con-
centrations b100 mg/dl and the pooled CV was b5% at glucose level
≥100 mg/dl.
3.2. Interference testing — hematocrit
For determining hematocrit interference, test samples with he-
matocrit of 15%, 20%, 30%, 50%, 60% and 65% were compared to the
control sample with a hematocrit of 42%. For each test strip lot, the
average difference between test samples and control samples was
≤5.1 mg/dl at glucose concentrations b100 mg/dl and ≤8.5% at
glucose ≥100 mg/dl (Table 2). Results of the arterial blood study
were also analyzed for hematocrit effect. Biases of meter results
were plotted against the sample hematocrit values. As shown in
Fig. 1, the regression slope was −0.01.
3.3. Interference testing — interfering substances
Twenty-ﬁve potentially interfering substances were each tested at
a level above the upper limit of therapeutic or normal concentration
(Table 3). They include reducing substances, common medications
and non-glucose sugars. At the speciﬁed test concentrations, allsubstances, except for xylose at the low glucose level, did not have
an interference effect.
3.4. Accuracy evaluation — capillary blood testing
Testing was completed on 163 capillary blood samples from 143
subjects. Each blood sample was tested in duplicate with 3 lots of
test strips, yielding 973 results. The range of glucose concentration
was 33–494 mg/dl. Regression analysis, scatter plots and bias plots
for individual meter results versus the comparative method mean
values are shown in Fig. 2. Overall, the mean absolute bias (MARD)
was 5.0%.
System accuracy analysis of each test strip lot showed: (1)≥98.8%
of results agreeing within 15 mg/dl or 15% (at glucose concentrations
≥100 mg/dl) of the reference; (2) 100% of results in zones A and B of
the Consensus Error Grid; (3) ≥96.6% of the results agreeing within
12 mg/dl or 12.5% (at glucose concentrations >100 mg/dl) of the
Table 4
System accuracy data analysis in accordance with the ﬁnal draft ISO 15197.
A. Glucose concentrations b100 mg/dl
Blood sample Within ±5 mg/dl Within ±10 mg/dl Within ±15 mg/dl
Capillary 136/222 (61.3%) 211/222 (95.0%) 222/222 (100%)
Venous EDTA 66/108 (61.1%) 97/108 (89.8%) 106/108 (98.1%)
Venous heparin 73/108 (67.6%) 101/108 (93.5%) 108/108 (100.0%)
Arterial 46/60 (76.7%) 59/60 (98.3%) 60/60 (100%)
B. Glucose concentrations ≥100 mg/dl
Blood sample Within ±5% Within ±10% Within ±15%
Capillary 532/751 (70.8%) 717/751 (95.5%) 744/751 (99.1%)
Venous EDTA 402/552 (72.8%) 536/552 (97.1%) 552/552 (100.0%)
Venous heparin 384/552 (69.6%) 514/552 (93.1%) 552/552 (100.0%)
Arterial 224/300 (74.7%) 290/300 (96.7%) 298/300 (99.3%)
C. Criterion A*
Blood sample Glucose concentration, mg/dl Within ±15 mg/dl or ±15%
Capillary 33–494 966/973 (99.3%)
Venous EDTA 58–372 658/660 (99.7%)
Venous heparin 57–372 660/660 (100%)
Arterial 66–236 358/360 (99.4%)
*Acceptable system accuracy performance requires 95% of BGMS results of each test strip lot individually to fall within ±15 mg/dl of the reference measurement procedure at
glucose concentrations b100 mg/dl or within ±15% at glucose concentrations >100 mg/dl.
D. Criterion Ba (Consensus Error Grid analysis)
Blood sample Consensus Error Grid zone Total
A B C D E
N % N % N % N % N %
Capillary 972 99.9 1 0.1 0 0.0 0 0.0 0 0.0 973
Venous EDTA 660 100 0 0.0 0 0.0 0 0.0 0 0.0 660
Venous heparin 660 100 0 0.0 0 0.0 0 0.0 0 0.0 660
Arterial 359 99.7 1 0.3 0 0.0 0 0.0 0 0.0 360
a Acceptable system accuracy performance requires 99% of BGMS results of the three test strip lots combined to fall within zones A and B of the Consensus Error Grid for type 1 diabetes.
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cose concentrations >75 mg/dl) of the reference. Results of the
three test strip lots are combined and shown in Tables 4 and 5.
3.5. Accuracy evaluation — venous blood testing
Testing was completed on 220 venous blood samples from 110 sub-
jects. Each blood sample was tested in duplicate with three lots of test
strips, yielding a total of 1320 results. The ranges of glucose concentra-
tion were 58–372 mg/dl and 57–372 mg/dl for the EDTA and heparin
blood samples, respectively. Regression analysis, scatter plots and bias
plots for individual meter results versus the comparative method
mean values are shown in Fig. 3. Overall, theMARDwere 4.2% in testing
the EDTA samples and 4.4% for the heparin samples.
For the EDTA samples as well as the heparin samples, system accu-
racy analysis of each test strip lot showed: (1) ≥99.1% of results agree-
ing within 15 mg/dl or 15% (at glucose concentrations ≥100 mg/dl) of
the reference; (2) 100% of results in zones A and B of the Consensus
Error Grid; (3) ≥96.8% of the results agreeing within 12 mg/dl
or 12.5% (at glucose concentrations >100 mg/dl) of the reference;Table 5
Analysis of accuracy in accordance with the new CLSI guideline (POCT12).
Blood sample Within ±12 mg/dl Within ±12.5%a
Capillary 216/222 (97.3%) 731/751 (97.3%)
Venous EDTA 103/108 (95.4%) 546/552 (98.9%)
Venous heparin 107/108 (99.1%) 535/552 (96.9%)
Arterial 59/60 (98.3%) 297/300 (99.0%)
a 100 mg/dl is used as threshold for calculating bias in %.
b First criterion: acceptable performance requires 95% of overall BGMS results to fall with
c 75 mg/dl is used as threshold for calculating bias in %. Second criterion: acceptable per(4)≥99.5% of the resultswithin 15 mg/dl or 20% (at glucose concentra-
tions >75 mg/dl) of the reference. Results of the three test strip lots are
combined and shown in Tables 4 and 5.
3.6. Accuracy evaluation — arterial blood testing
Testingwas completed on 120 arterial blood samples from intensive
care unit and operating room patients at a medical center. Each blood
sample was tested once with three lots of test strips, yielding 360 re-
sults. The ranges of glucose concentration were 66–236 mg/dl; he-
matocrit, 21–50%, pH, 7.06–7.53; pO2, 36–268 mm Hg. Regression
analysis and scatter plots for individual meter results versus the
comparative method mean values are shown in Fig. 4. Overall, the
MARD was 3.9%.
System accuracy analysis of each test strip lot showed: (1)≥99.2%
ofmeter results agreeingwithin 15 mg/dl or 15% (at glucose concentra-
tions ≥100 mg/dl) of the reference; (2) 100% of meter results in zones
A and B of the Consensus Error Grid; (3) ≥98.3% of the results
agreeing within 12 mg/dl or 12.5% (at glucose concentrations
>100 mg/dl) of the reference; (4) 100% of the results within 15 mg/dlWithin ±12 mg/dl or 12.5%a, b Within ±15 mg/dl or 20%c
947/973 (97.3%) 972/973 (99.9%)
649/660 (98.3%) 659/660 (99.8%)
642/660 (97.3%) 660/660 (100%)
356/360 (98.9%) 360/360 (100%)
in these limits.
formance requires 98% of overall BGMS results to fall within these limits.
Fig. 3. Scatter plot (A) and bias plots (B) for venous blood glucose results. (A) Regression analysis showed: slope = 0.98, intercept = 5.4 mg/dL, r = 0.99, n = 660 for EDTA sam-
ples; slope = 1.00, intercept = 4.3 mg/dL, r = 0.99, n = 660 for heparin samples. (B) Analysis showed: mean bias = 1.5 mg/dL or 1.6%, MARD = 4.2%, n = 660 for EDTA sam-
ples; mean bias = 4.2 mg/dL or 3.0%, MARD = 4.4%, n = 660 for heparin samples.
248 R. Brazg et al. / Clinica Chimica Acta 421 (2013) 243–250or 20% (at glucose concentrations >75 mg/dl) of the reference. Re-
sults of the three test strip lots are combined and shown in Tables 4
and 5.
4. Discussion
We evaluated the clinical performance of the FreeStyle Precision
Pro system, a new POCT device designed to enhance accuracy of
blood glucose monitoring. Our study results were analyzed and
presented in this report using the more stringent speciﬁcations and
recommendations proposed in the ﬁnal draft ISO 15197 [4] and CLSI
POCT12 [5].
The pooled standard deviation and pooled CV for each glucose
concentration were calculated using the measurement results from
all three test strip lots in the repeatability and intermediate precision
studies. It is also stated in the ﬁnal draft ISO 15197 that (1) the
criteria for measurement repeatability and intermediate measure-
ment precision should be related to the system accuracy performance
criteria; (2) separate criteria for minimum acceptable precision andbias are not speciﬁed in this International Standard; (3) the study
protocol shall specify the acceptance criteria. In these studies, the
pooled SD ranged from 2.2 to 3.8 mg/dl at glucose b100 mg/dl and
the pooled CV ranged from 2.9 to 4.1%. They met the acceptance
criteria from the study protocol, which speciﬁed that the pooled SD
shall be ≤5 mg/dl at glucose concentrations b100 mg/dl and the
pooled CV shall be ≤5% at glucose concentrations ≥100 mg/dl.
Because the accuracy of BGMS can be affected by many factors in-
cluding sample hematocrit and interfering substances [12,13], a new
section on evaluating interference was added to the ﬁnal draft ISO
15197. Using the new criteria, we found no interference effect with
the three test strip lots at ﬁve glucose concentrations and six hemat-
ocrit levels ranging from 15% to 65%. We also examined results of the
accuracy studies and found no apparent effect due to the sample he-
matocrit as shown by a regression slope close to zero when biases of
meter results were plotted against the sample hematocrit values. The
acceptable performance with the FreeStyle Precision Pro system at
varying hematocrit levels was likely due to an automatic compensa-
tion for sample hematocrit built in the meter.
Fig. 4. Scatter plot (A) and bias plots (B) for arterial blood glucose results. (A) Regression
analysis showed: slope = 1.08, intercept = −9.2 mg/dL, r = 0.98, n = 360. (B) Analy-
sis showed: mean bias = 1.2 mg/dL or 0.6%, MARD = 3.9%, n = 360.
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ing substances, non-glucose sugars and common medications, each
at a level above the upper limit of therapeutic or normal concentra-
tion. Of the 25 substances tested, only xylose interfered, showing a
positive bias at the low glucose level. A risk assessment on the xylose
interference indicates that the severity is represented by a signiﬁcant
increase in the glucose results during a xylose absorption test. How-
ever the likelihood of occurrence is near improbable because: (1) xy-
lose blood concentration is high enough to interfere only within a
24-hour window immediately following the xylose administration
for the absorption test since the absorbed xylose is rapidly excreted
in urine [14]; and (2) the xylose absorption test is rarely performed
in medical centers today. This explains why there has not been any
reported adverse event caused by xylose interference [15–17] even
though test strips sensitive to xylose have been in use in health care
facilities for over 10 years.
For assessment of system accuracy, mean absolute bias, also known
as mean absolute relative difference (MARD), is a measure of the aver-
age disparity between test device results and the comparative methodresults. The smaller the MARD, the more accurate the device is consid-
ered. However, MARD is seldom presented in BGMS evaluation reports.
One such publication showed MARD ranging from 4.9% to 9.7% for cap-
illary blood testing with ﬁve recently introduced BGMS [18]. In our
studies, the MARD were 3.9–5.0% for the various blood sample types.
Although there are no outcome studies that substantiate improved
patient beneﬁts from greater accuracy of a BGMS, it is logical to sug-
gest that medical staff may be able to better control the patient's
blood glucose levels if the BGMS is more accurate. Computer simula-
tion modeling has shown large improvements in glycemic control
and in detection of hypoglycemia and decreases in the frequency of
two-category insulin dosing errors in tight glycemic control protocols
employing intravenous infusion of insulin when the total error of glu-
cose measurement decreases from 20% toward 10% [19–21]. The cur-
rent accuracy speciﬁcations for all BGMS require 95% of the results
within ±15 mg/dl of the reference or within ±20% at glucose con-
centrations ≥75 mg/dl. The new POCT12 increases that requirement
from 95% to 98%. In addition, it requires 95% of the BGMS results fall-
ing within the much tighter limits of within ±12 mg/dl of the refer-
ence or within ±12.5% at glucose concentrations ≥100 mg/dl. In our
studies, the FreeStyle Precision Pro system met all these require-
ments. Compared to its predicate (the Precision Xceed Pro system),
the FreeStyle Precision Pro system makes more measurements and
uses more signals from the glucose electrochemical reaction to in-
crease accuracy; it also performs more integrity checks to detect po-
tential errors during each glucose test.
In summary, we completed a multicenter evaluation of the Free-
Style Precision Pro system and applied more stringent accuracy
criteria to the results. The system accuracy evaluation was completed
with 503 blood samples from capillary, venous and arterial sources,
yielding 2653 meter results. Our ﬁndings established that the Free-
Style Precision Pro system met the tighter accuracy criteria speciﬁed
in the ﬁnal draft ISO 15197 and the new POCT12.
Beyond the scope of this report, other features and performance of
the FreeStyle Precision Pro system that are designed to optimize POCT
includewireless transfer of patient data and test results inWiFi enabled
facilities, built-in camera for accurate scanning of one dimensional and
two dimensional barcodes, rapid blood ketone (betahydroxybutyrate)
testing, and individually packaged test strips to minimize unintended
exposure or contamination.
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